Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) CAO Michael R. Megna sold 9,051 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total transaction of $203,194.95. Following the completion of the transaction, the chief accounting officer now owns 26,528 shares in the company, valued at approximately $595,553.60. This trade represents a 25.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Kiniksa Pharmaceuticals Stock Up 2.0 %
Shares of NASDAQ:KNSA opened at $22.61 on Monday. The company’s 50 day moving average price is $19.99 and its two-hundred day moving average price is $22.13. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $16.56 and a 12-month high of $28.15. The firm has a market cap of $1.64 billion, a PE ratio of -161.49 and a beta of 0.48.
Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. During the same period last year, the company posted $0.35 EPS. The business’s revenue was up 46.9% on a year-over-year basis. On average, research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.
Wall Street Analysts Forecast Growth
Institutional Trading of Kiniksa Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the company. Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $50,000. Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the 4th quarter worth approximately $61,000. KLP Kapitalforvaltning AS bought a new position in Kiniksa Pharmaceuticals in the 4th quarter valued at approximately $158,000. Bellevue Group AG bought a new position in Kiniksa Pharmaceuticals in the 4th quarter valued at approximately $160,000. Finally, Tower Research Capital LLC TRC lifted its stake in Kiniksa Pharmaceuticals by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock valued at $168,000 after purchasing an additional 4,575 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
See Also
- Five stocks we like better than Kiniksa Pharmaceuticals
- About the Markup Calculator
- How to Build the Ultimate Everything ETF Portfolio
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- 3 REITs to Buy and Hold for the Long Term
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.